医学
Paper Review Records
全部论文审稿周期
10 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
First-Line Integration of Local Ablative Therapy With EGFR Tyrosine Kinase Inhibitors in Advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis
作者Leonardo Brunetti; Giacomo Colella; Giuseppina Rita Di Fazio; Giulia La Cava; Valentina Santo; Federica Pecci; Julia K. Rotow; Jessica R. Bauman; Amin H. Nassar; Elio Adib; Abdul Rafeh Naqash; Marco Tagliamento; Roberto Ferrara; Fabrizio Citarella; Marco Russano; Biagio Ricciuti; Corinne Faivre-Finn; Lizza E.L. Hendriks; Antonio Passaro; Bruno Vincenzi; Fabian Acker; Lisa Derosa; David Planchard; Hugo J.W.L. Aerts; Silvia Novello; Francesco Passiglia; Carlo Greco; Sara Ramella; Alessio Cortellini
作者单位Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy; Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; GROW Research Institute for Cancer and Reproduction, Maastricht University, Maastricht, The Netherlands; Department of Surgery and Cancer, Imperial College of London, London, United Kingdom; Medical Oncology, ASST Fatebenefratelli-Sacco, Milano, Italy; Department of Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Section of Medical Oncology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts; Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, Oklahoma; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy; IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom The Christie NHS Foundation Trust, Manchester, United Kingdom; Department of Pulmonary Diseases, GROW—Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy; Department of Medicine II, Hematology and Oncology, University Hospital, Goethe University Frankfurt, Frankfurt, Germany; Tumor Immunology and Cancer Immunotherapy, Université Paris-Saclay, Gustave Roussy, Inserm UMR1015, Villejuif, France; Department of Medical Oncology, Gustave Roussy, Villejuif, France; Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France Faculty of Medicine, Paris-Saclay University, Paris, France; Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Harvard Institutes of Medicine, Boston, Massachusetts; Radiology and Nuclear Medicine, CARIM and GROW, Maastricht University, Maastricht, The Netherlands; Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Turin, Italy; Operative Research Unit of Radiation Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy
YAP1 Defines an Emergent, Plastic Population of Relapsed SCLC
作者C. Allison Stewart; Kavya Ramkumar; Runsheng Wang; Yuanxin Xi; Alexa Halliday; Lixia Diao; Qi Wang; Alejandra Serrano; Sarah Groves; Simon Heeke; Azusa Tanimoto; Laura Kaiser; Whitney Lewis; Mukulika Bose; Pedro Rocha; Loukia Karacosta; Vito Quaranta; Jing Wang; Julie George; Luisa Maren Solis Soto; Bingnan Zhang; John V. Heymach; Lauren A. Byers; Carl M. Gay
作者单位Department of Thoracic/Head & Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia; Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Medical Oncology, Thoracic Tumors Unit, Vall d’Hebron University Hospital, Barcelona, Spain; Institute for Experiential AI, Northeastern University, Boston, Massachusetts; Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine and University Hospital Cologne, University Hospital of Cologne, Cologne, Germany
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial
作者Suresh Senan; Byoung Chul Cho; Konstantin K. Laktionov; Yoshitaka Zenke; Ki Hyeong Lee; Qiming Wang; Alejandro Navarro; Eva Lotte Buchmeier; Sema Sezgin Goksu; Andrzej Badzio; Anhui Shi; Davey B. Daniel; Milada Zemanova; Puneeth Iyengar; Luis Paz-Ares; Leah Szadkowski; Priti Chugh; W. Victoria Lai; David R. Spigel
作者单位Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russia; National Cancer Center Hospital East, Kashiwa, Japan; Chungbuk National University Hospital, Cheongju, Republic of Korea; The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China; Hospital Vall d'Hebron and Vall d’Hebron Institute of Oncology, Barcelona, Spain; Hospitals of the City of Cologne gGmbH, Cologne, Germany; Akdeniz University Medical Faculty, Antalya, Türkiye; Medical University of Gdansk, Gdansk, Poland; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China; Tennessee Oncology PLLC, Nashville, Tennessee; First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic; Memorial Sloan Kettering Cancer Center, New York, New York; Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, Spain; AstraZeneca, Mississauga, Ontario, Canada; AstraZeneca, Waltham, Massachusetts; AstraZeneca, New York, New York; Sarah Cannon Research Institute, Nashville, Tennessee
Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group
作者Aaron C. Tan; Bin-Chi Liao; Molly Li; David Lee; Yuji Uehara; Lucksamon Thamlikitkul; Jia-Tao Zhang; Meimei Zheng; Chee Khoon Lee; Nick Pavlakis; Thomas John; Ross A. Soo; Anders Skanderup; Pei Jye Voon; Beung-Chul Ahn; Sehhoon Park; Hidetoshi Hayashi; Yasushi Goto; Hidehito Horinouchi; Yasushi Yatabe; Thanyanan Reungwetwattana; James Chih-Hsin Yang; Dong-Wan Kim; Tony Mok; Daniel S.W. Tan; Yi-Long Wu; Myung-Ju Ahn
作者单位Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China; Sunway Medical Centre, Kuala Lumpur, Malaysia; Department of Thoracic Oncology, National Cancer Centre Hospital, Chuo-ku, Tokyo, Japan; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore; Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore; Department of Radiotherapy, Oncology and Palliative Care, Hospital Umum Sarawak, Kuching, Sarawak, Malaysia; Center for Lung Cancer, Division of Hematology and Oncology, Department of Internal Medicine, Research Institute and Hospital, National Cancer Center, Gyeonggi-do, Republic of Korea; Department of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan; Department of Diagnostic Pathology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Internal Medicine, Seoul National University Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial
作者Benjamin Levy; Luis Paz-Ares; Chien-Chung Lin; Scott Herbert; Tsung-Ying Yang; Anthony Tolcher; Yanyan Lou; Yoshitaka Zenke; Diego Cortinovis; Enriqueta Felip; Manuel Domine; Konstantinos Leventakos; Emiliano Calvo; Atsushi Horiike; Edward Pan; Priyanka Basak; Daisy Lin; Wen Gu; Rachel Chiaverelli; Michael J. Chisamore; Yasushi Goto
作者单位The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Baltimore, Maryland; Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense & CiberOnc, Madrid, Spain; Department of Internal Medicine, National Cheng Kung University Hospital and Tainan Hospital, Ministry of Health and Welfare, Tainan City, Taiwan; Quantum, Santa Fe, New Mexico; Department of Chest Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; NEXT Oncology, San Antonio, Texas; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; Medicine and Surgery Department, University of Milano-Bicocca, Milano, Italy; Vall d’Hebron Hospital Campus, Vall d’Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Spain; Department of Oncology, Hospital Universitario Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain; Department of Oncology, Mayo Clinic, Rochester, Minnesota; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan;; Daiichi Sankyo, Inc., Basking Ridge, New Jersey; Oncology Early Development – External Collaborations, Merck & Co., Inc., Rahway, New Jersey; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial
作者Yun Fan; Yanqiu Zhao; Dingzhi Huang; Jun Zhao; Tai Qin; Wanyu He; Chenqi Chen; Pu Sun; Kirsha Naicker; Yong Song
作者单位Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China; Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department I of Thoracic Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China; Clinical Development–Solid Tumors, BeOne Medicines, Ltd., Beijing, China; Statistics, BeOne Medicines, Ltd., New York, New York; Clinical Biomarkers, BeOne Medicines, Ltd., Beijing, China; Clinical Development–Solid Tumors, BeOne Medicines, Ltd., London, United Kingdom; Department of Respiratory and Critical Care Medicine, Jinling Hospital, Nanjing Medical University, Nanjing, China
Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC
作者Santiago Ponce; Miguel Ruiz-Torres; Alejandro Falcón; Gregory M. Cote; Reyes Bernabé; Jessica J. Lin; Juan Manuel Coya; Marta Jiménez-Muñoz; Pablo Fernández-Puyuelo; Amparo Sánchez; Jon Zugazagoitia; Alvaro Ucero; Javier Baena; Helena Bote de Cabo; Mercedes Herrera; Javier Torres-Jiménez; Maria Zurera; Carmen Kahatt; Jose Antonio Lopez-Vilariño; Sara Martinez; Mariano Siguero; Marcos Malumbres; Irene Ferrer; Luis Paz-Ares
作者单位Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; Centro Nacional de Investigaciones Oncológicas (CNIO)-Hospital 12 de Octubre (H12O) Lung Cancer Clinical Cancer Research Unit, Instituto de Investigación Biomédica i+12 and CNIO, Madrid, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain; Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain; Massachusetts General Hospital, Boston, Massachusetts; Physiology and Medicine Departments, Universidad Complutense, Madrid, Spain; Oncology Clinical Development, Pharma Mar, Colmenar Viejo, Madrid, Spain; Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort
作者Oliver Illini; Anna-Carina Hund; Hans-Georg Kopp; Mor Moskovitz; Giannis Mountzios; Wolfgang M. Brueckl; Martin Früh; Marie-Elisabeth Leßmann; Petros Christopoulos; Albrecht Stenzinger; Michael Thomas; Roni Gillis; Nir Peled; Fabian Acker; Alfredo Addeo; Andriani Charpidou; Christian Grohé; Horst-Dieter Hummel; Laetitia Mauti; Sacha I. Rothschild; Sabine Schmid; Christian Schumann; Damien Urban; Robert Wurm; Simon Ekman; Marcus Skribek; Franziska Glanemann; Marcel Wiesweg; Christoph Jakob Ackermann; Sofia Agelaki; Petra Hoffknecht; Marko Jakopović; Jens Kern; David König; Katharina Kostenzer; Cornelia Kropf-Sanchen; Eckart Laack; David Lang; Laurenz Nagl; Georg Pall; Martin Reck; Waleed Kian; Anna T. Allemann; Jürgen Alt; David Araújo; Hanibal Bohnenberger; Alexandros Bokas; Hannah Fabikan; Krainer-Jacobs Julie; Christoph Weinlinger; Adrianus Johannes de Langen; Evangelos Georgios Fergadis; Rieke Fischer; Elena Fountzilas; Patrizia Froesch; Nikolaj Frost; Frank Griesinger; Franziska Jordan; Charisios Karanikiotis; Barbara Kiesewetter; Ippokratis Korantzis; Andrea Lopes Machado; Panagiota Economopoulou; Arnold Pilz; Patrick Reimann; Achim Rittmeyer; Akram Saad; Konstantinos Samitas; Karsten Schulmann; Riyaz Shah; Jan Alexander Stratmann; Hossein Taghizadeh; Kai Tammoscheit; Amanda Tufman; Jan-Phillip Weber; Ewald Wöll; Arschang Valipour; Tobias R. Overbeck; Maximilian J. Hochmair
作者单位Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria; Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria; Department of Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany; National Network Genomic Medicine, Cologne, Germany; Department of Hematology, Oncology, and Palliative Care, Robert Bosch Center for Tumor Diseases, Stuttgart, Germany; Davidoff Cancer Center, Beilinson MC, Petah Tikva, Israel; 4th Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece; Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany; Department of Oncology and Hematology, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland; Department of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland; Department of Medicine I, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany; Institute for Pathology, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany; Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Germany; Department of Translational Pulmonology, Heidelberg University Hospital, Heidelberg, Germany; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel; Goethe University Frankfurt, University Hospital, Department of Medicine 2, Hematology and Oncology, Frankfurt, Germany; Oncology Department, University Hospital Geneva, Geneva, Switzerland; Oncology Unit, 3rd Department of Internal Medicine and Laboratory Medical School, National and Kapodistrian University of Athens, Sotiria General Hospital, Athens, Greece; Klinik für Pneumologie, Evangelische Lungenklinik, Berlin, Germany; Translational Oncology/Early Clinical Trial Unit (ECTU), Bavarian Cancer Research Center, National Center for Tumor Diseases, Comprehensive Cancer Center Mainfranken and University Hospital Würzburg, Würzburg, Germany; Medizinische Onkologie, Kantonsspital Winterthur, Winterthur, Switzerland; Department of Internal Medicine, Center of Oncology & Hematology, Cantonal Hospital Baden, Baden, Switzerland and University of Basel, Medical Faculty, Basel, Switzerland; Respiratory Critical Care, Allgäu Clinics, Kempten and Immenstadt, Kempten, Germany; Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; Department of Thoracic Oncology, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Department of Oncology and Haematologie Thun-Spiez-Berner-Oberland, Thun, Switzerland; Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece; Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece; Department of Thoracic Oncology, Niels-Stensen-Kliniken, Franziskus-Hospital Harderberg, Georgsmarienhütte, Germany; Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia; KWM-Standort Missioklinik, Würzburg, Germany; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland; Department of Pneumology, LKH Hochzirl-Natters, Tirol Kliniken, Natters, Austria; Department II for Internal Medicine, University Hospital of Ulm, Ulm, Germany; Hemato-Oncology Hamburg, Hamburg, Germany; Department of Internal Medicine 4 - Pneumology, Kepler University Hospital, Johannes Kepler University Linz, Linz, Austria; Department of Internal Medicine V - Haematology and Oncology, Tirol Kliniken, Medical University Innsbruck, Innsbruck, Austria; Department of Internal Medicine 2, Kardinal Schwarzenberg Hospital, Schwarzach im Pongau, Austria; Department of Thoracic Oncology, LungenClinic, Grosshansdorf, Germany; Airway Research Center North, German Center for Lung Research, Giessen, Germany; Oncology Department, Samson Assuta Ashdod University Hospital, Ashdod, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Department of Medical Oncology, Tumorzentrum, Luzerner Kantonsspital, Spitalstrasse, Luzern, Switzerland; Department of Hematology and Medical Oncology, University Medical Center Mainz, Mainz, Germany; Department of Pulmonology, Unidade Local de Saúde São João, Porto, Portugal; Faculty of Medicine, Universidade do Porto, Porto, Portugal; Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany; 1st Department of Clinical Oncology, Theagenio Cancer Hospital of Thessaloniki, Thessaloniki, Greece; Department of Thoracic Oncology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands; Medical Oncology Department, Metaxa Cancer Hospital, Piraeus, Greece; Department I of Internal Medicine, Center for Integrated Oncology (CIO), University Hospital of Cologne, Cologne, Germany; European University Cyprus, German Oncology Center, Nicosia, Cyprus; Department of Medical Oncology, St Luke's Clinic, Thessaloniki, Greece; Istituto Oncologico della Svizzera Italiana (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland; Department of Infectious Diseases and Pulmonary Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt Universität Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Hematology and Medical Oncology, Pius-Hospital, Department of Internal Medicine-Oncology, University Medicine Oldenburg, Oldenburg, Germany; Department of Pneumology, University Hospital Salzburg, Salzburg, Austria; Department of Medical Oncology, Euromedica - Kianous Stavros Clinic, Thessaloniki, Greece; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria; St Luke’s Hospital, Panorama, Thessaloniki, Greece; Department of Pulmonary Oncology - ULS Santa Maria/Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Oncology Unit, Second Department of Internal Medicine, Attikon University Hospital, Athens, Greece; Department of Respiratory and Pulmonary Diseases, Clinic Penzing, Vienna Healthcare Group, Vienna, Austria; Ludwig Boltzmann Institute for Lung Health, Vienna, Austria; Department of Haematology, Oncology, Gastroenterology and Infectiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Department of Thoracic Oncology, LKI Lungenfachklinik Immenhausen, Immenhausen, Germany; Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Israel; 7th Respiratory Department, Athens Chest Hospital “Sotiria,” Athens, Greece; Department of Pneumology, Division of Thoracic Oncology and Palliative Care, Lungenklinik Hemer, Hemer, Germany; GenesisCare Maidstone, Kings Hill, West Malling, United Kingdom; UKS Homburg, Homburg, Germany; Oncology, University Hospital St. Pölten, St. Pölten, Lower Austria, Austria; Karl Landsteiner Institute of Nephrology and Hematooncology, Lower Austria, Austria; Hessenklinik Stadtkrankenhaus Korbach, Korbach, Germany; Department of Internal Medicine V, Comprehensive Pneumology Center (CPC-M), Ludwig-Maximilians-Universität Munich, Germany; German Center for Lung Research (DZL), Bavarian Center for Cancer Research (BZKF), Germany; MVZ Oncology and Hematology, Sachsenring, Köln, Germany; Head of Department of Internal Medicine, Head of Laboratory Unit, Executive Medical Director, Krankenhaus St. Vinzenz, Zams, Austria
Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay
作者Jamie Feng; Sameena Khan; Thomas K. Waddell; Kazuhiro Yasufuku; Zachary Coyne; Deirdre Kelly; Nicholas Meti; Najib Safieddine; Michael Ko; Andrew Pierre; Shaf Keshavjee; Elliot Wakeam; Laura Donahoe; Marcelo Cypel; Jonathan Yeung; Marc de Perrot; Negar Ahmadi; Sayf Gazala; Carmine Simone; David Parente; Mary R. Rabey; Jennifer H. Law; Janice J.N. Li; Alexandra Salvarrey; Lisa W. Le; Andrew Seto; Michael Cabanero; Ming-Sound Tsao; Christodoulos Pipinikas; Amber Chevalier; Scott V. Bratman; Natasha B. Leighl
作者单位Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Division of Thoracic Surgery, University Health Network (UHN), Toronto, Ontario, Canada; Division of Thoracic Surgery, Michael Garron Hospital, Toronto, Ontario, Canada; Division of Thoracic Surgery, Unity Health Toronto, Toronto, Ontario, Canada; Department of Biostatistics, University Health Network, Toronto, Ontario, Canada; Division of Pathology and Cytogenetics, Laboratory Medicine Program, UHN, Toronto, Ontario, Canada; NeoGenomics Inc., Fort Myers, Florida; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose Computed Tomography Lung Cancer Screening
作者Anna Zanghì; Massimo Moro; Orazio Fortunato; Miriam Segale; Federica Sabia; Paola Suatoni; Roberta E. Ledda; Luigi Rolli; Alfonso Marchianò; Ugo Pastorino; Gabriella Sozzi; Mattia Boeri
作者单位Unit of Epigenomics & Biomarkers of Solid Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Unit of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Section of Radiology, Unit of Surgical Sciences, Department of Medicine and Surgery (DiMeC), University of Parma, Parma, Italy; Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。